Fig. 1.

Chronic treatment with the nucleoside reverse transcriptase inhibitor zalcitabine (ddC) induced mechanical and thermal hypersensitivity. a Following 13 weeks of chronic ddC treatment (3 mg/kg/day), mechanical withdrawal thresholds were attenuated at treatment week 9 and remained attenuated thereafter. b Paw withdrawal latencies to heat stimuli were attenuated in mice on 13 weeks of chronic ddC treatment (3 mg/kg/day). Data are presented as the mean ± standard error of the mean (SEM). Bonferroni correction for multiple comparisons. Asterisks indicate a significant difference at P < 0.05 between the ddC-treated mice and the control mice (saline). n = 10 mice/group